Introduction Implementation of low-intensity, evidence-based psychological interventions can help meet the mental health and ...
First Patient Dosed with Intranasal Foralumab in Randomized, Placebo-Controlled Phase 2 TrialBuilds on Recent Evidence of Persistent Neuroinflammation in Alzheimer's Patients Treated with Anti-Amyloid ...
First Patient Dosed with Intranasal Foralumab in Randomized, Placebo-Controlled Phase 2 TrialBuilds on Recent Evidence of Persistent Neuroinflammation in Alzheimer’s Patients Treated with Anti-Amyloid ...
Châtillon, France, December 16, 2025 DBV Technologies Announces Positive Topline Results from Phase 3 VITESSE Trial of VIASKIN Peanut Patch in Peanut Allergic Children Aged 4-7 Years VITESSE ...
DBV Technologies is headquartered in Châtillon, France, with North American operations in Warren, NJ. The Company’s ordinary ...
Introduction Cognitive impairment is a common consequence after stroke. Intermittent theta burst stimulation (iTBS) has emerged as a promising cognitive therapy. However, traditional iTBS typically ...
-- First Patient Expected to be Dosed Next Week with Intranasal Foralumab -- PET Scan Shows Presence of Untreated Neuroinflammation in Alzheimer's Patient on Leqembi (R) (Lecanemab) Anti-Amyloid ...
Providing surgeons feedback and education on their performance significantly improved the quality of bladder cancer ...
Key milestone achieved as Company advances clinical program to full approval trial of ateganosine sequenced with a checkpoint inhibitor in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback